Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DateTimeSourceHeadlineSymbolCompany
02/05/202421:00GlobeNewswire Inc.Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
25/04/202421:00GlobeNewswire Inc.Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2NASDAQ:KYMRKymera Therapeutics Inc
08/04/202421:00GlobeNewswire Inc.Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
09/03/202402:00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
05/03/202410:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202410:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202410:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202409:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202409:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
28/02/202423:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
28/02/202408:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
22/02/202423:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KYMRKymera Therapeutics Inc
22/02/202423:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
22/02/202423:00GlobeNewswire Inc.Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
15/02/202423:00GlobeNewswire Inc.Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22NASDAQ:KYMRKymera Therapeutics Inc
10/02/202411:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
10/02/202408:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
31/01/202423:00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceNASDAQ:KYMRKymera Therapeutics Inc
10/01/202401:17GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
10/01/202401:15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
06/01/202408:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
06/01/202408:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
05/01/202422:00GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $275 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
05/01/202408:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
05/01/202408:01GlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
04/01/202423:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
04/01/202423:00GlobeNewswire Inc.R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
03/01/202409:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
02/01/202423:00GlobeNewswire Inc.Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024NASDAQ:KYMRKymera Therapeutics Inc
13/12/202323:00GlobeNewswire Inc.Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4NASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR